Describe the biochemical mechanism where high levels of fatty acid oxidation inhibit glucose uptake and utilization in muscle and adipose tissue and explain its relevance to insulin resistance

University	Bangladesh University of Health Sciences
Name	Tanjila Begum
ID	0672320003011052
Semester	Fall 23
Department	Biochemistry and Cell Biology
Course Title	Metabolism-II
Date	November 2026

Abstract

Muscle and fat (adipose) tissue can burn two main fuels: glucose (sugar) and fatty acids (fat). When the blood has too many free fatty acids — as happens in obesity — these tissues burn more fat and take up and use less glucose. This idea was first described by Philip Randle and colleagues in 1963 and is called the **glucose–fatty acid cycle** or **Randle cycle**. In the classic model, products of fat burning (acetyl-CoA, NADH and citrate) switch off three key enzymes of glucose use: pyruvate dehydrogenase, phosphofructokinase and hexokinase. Later studies in humans showed that the biggest problem is actually earlier, at the step where glucose enters the cell through the GLUT4 transporter. Fat-derived molecules such as diacylglycerol, ceramides and fatty acyl-CoA build up inside the cell, switch on enzymes like PKCθ, and damage the insulin signal. Fat overload also causes incomplete fat burning in mitochondria, oxidative stress and inflammation. Together these changes explain a large part of **insulin resistance**, the main defect behind type 2 diabetes. This paper explains each step in simple language and discusses why it matters for prevention and treatment.

1. Introduction

After a meal, insulin tells muscle and fat cells to take sugar out of the blood. Skeletal muscle alone takes up about 70–80% of the glucose after a meal, so it is the most important tissue

for keeping blood sugar normal. Fat tissue takes up less glucose, but it controls how much fat is released into the blood.

The body is normally **metabolically flexible**: after a meal, muscle burns mostly glucose; during fasting, it switches to mostly fat. In obesity and type 2 diabetes this flexibility is lost. Blood free fatty acid (FFA) levels stay high, muscle keeps burning fat, and glucose stays in the blood. The cell "ignores" insulin — this is called **insulin resistance**.

The question this paper answers is simple: **how does too much fat burning stop the cell from using glucose, and why does this cause insulin resistance?**

2. The classic mechanism: the glucose–fatty acid cycle

Glucose and fatty acids both end up as **acetyl-CoA**, which enters the TCA (Krebs) cycle. Because they share this end point, the two fuels compete with each other. Randle and colleagues studied rat heart and diaphragm muscle and found that adding fatty acids reduced glucose uptake and use (Randle et al., 1963). They explained it as a chain of three "brakes":

2.1 Brake 1 — Pyruvate dehydrogenase (PDH) is switched off

- β-oxidation of fat makes a lot of **acetyl-CoA** and **NADH**.
- The high **acetyl-CoA/CoA** and **NADH/NAD$^+$** ratios directly inhibit the PDH complex.
- They also activate **PDH kinase (especially PDK4)**, which phosphorylates and turns off PDH.
- Result: pyruvate from glucose cannot enter the mitochondria to be burned. Pyruvate is changed to lactate or alanine instead.

This is the fastest and strongest part of the cycle.

2.2 Brake 2 — Phosphofructokinase-1 (PFK-1) is slowed

- Extra acetyl-CoA joins with oxaloacetate and forms more **citrate**.
- Citrate leaves the mitochondria into the cytosol and **inhibits PFK-1**, the main control enzyme of glycolysis.
- Result: glycolysis slows down and **glucose-6-phosphate (G6P)** builds up.

2.3 Brake 3 — Hexokinase is blocked and glucose uptake falls

- Built-up **G6P inhibits hexokinase II**.
- Free glucose then builds up inside the cell, the concentration gradient falls, and **less glucose enters the cell**.

2.4 Summary of the classic model

> More fat burning → ↑ acetyl-CoA, NADH, citrate → PDH ↓ → PFK-1 ↓ → G6P ↑ → hexokinase ↓ → glucose uptake ↓

Extra G6P is pushed into glycogen storage at first, but overall glucose **oxidation** falls the most (Hue & Taegtmeyer, 2009).

3. The insulin signal itself is damaged

3.1 What human studies showed

In the 1990s, Gerald Shulman's group used magnetic resonance spectroscopy to look inside human muscle during a lipid infusion. If the classic model were the whole story, G6P should have **gone up**. Instead, G6P **went down**, and this fall came before the fall in glycogen making. This meant the main block was at the very first step: **glucose transport by GLUT4**. Fatty acids were also found to reduce insulin-stimulated, IRS-1–linked PI3-kinase activity (Samuel & Shulman, 2012).

So in humans, the problem is less about "fuel competition inside the mitochondria" and more about **fat molecules jamming the insulin signal**.

3.2 Normal insulin signaling (for comparison)

1. Insulin binds the **insulin receptor** → receptor phosphorylates **IRS-1** on **tyrosine**.
2. IRS-1 activates **PI3-kinase** → makes PIP_3.
3. PIP_3 activates **Akt (protein kinase B)**.
4. Akt (via AS160/TBC1D4) moves **GLUT4** from storage vesicles to the cell membrane.
5. Glucose enters the cell.

3.3 How fat molecules break this signal

When fatty acids come into the cell faster than mitochondria can burn them, they are stored as "toxic" lipid intermediates:

a) Diacylglycerol (DAG) and PKCθ

- DAG builds up inside the muscle cell.
- DAG activates **novel protein kinase C** enzymes — **PKCθ** in muscle (PKCε in liver).
- PKCθ phosphorylates **IRS-1 on serine** (not tyrosine).

- Serine-phosphorylated IRS-1 cannot activate PI3-kinase properly → Akt stays low → **GLUT4 stays inside the cell** → glucose uptake falls.

b) Ceramides

- Saturated fats like palmitate are made into **ceramides**.
- Ceramides block **Akt** in two ways: they activate protein phosphatase 2A (PP2A), which removes the activating phosphate from Akt, and they activate PKCζ, which stops Akt from reaching the membrane.
- Blocking ceramide synthesis protects animals from fat-induced insulin resistance.

c) Long-chain fatty acyl-CoA

- Also builds up and can feed both DAG and ceramide production and activate stress kinases.

3.4 Incomplete fatty acid oxidation and mitochondrial stress

In obese animals, β-oxidation runs fast but the TCA cycle and electron transport chain cannot keep up. This leads to:

- Build-up of **acylcarnitines** (half-burned fat pieces).
- Extra **reactive oxygen species (ROS)** from overloaded mitochondria.
- Oxidative stress that activates stress kinases and further damages insulin signaling.

When fat entry into mitochondria is reduced in mice, the animals are **protected** from insulin resistance. So the problem is not fat burning by itself, but **fat burning that is too fast and incomplete**.

3.5 Inflammation

Saturated fatty acids can activate **Toll-like receptor 4 (TLR4)**. This switches on **JNK** and **IKKβ/NF-κB**. JNK and IKKβ also phosphorylate IRS-1 on serine, adding to the damage caused by PKCθ.

4. What happens in adipose (fat) tissue

Fat tissue as a victim

- Fat cells also take up glucose through **GLUT4**.
- High fatty acids and enlarged, stressed fat cells lower GLUT4 and the insulin signal.
- Result: fat cells take up **less glucose**.
- Less glucose → less **glycerol-3-phosphate** → fat cells store fatty acids back as triglyceride less well.

Fat tissue as a cause

- Normally insulin **stops lipolysis** by inhibiting **hormone-sensitive lipase (HSL)** and **ATGL**.
- In insulin-resistant fat tissue this "stop" signal fails → **more free fatty acids leak into the blood**.
- Enlarged fat cells release more **TNF-α** and **IL-6** (inflammation).
- They release less **adiponectin**, a protective hormone that improves fat burning and insulin sensitivity.
- The extra fatty acids travel to **muscle and liver** and drive the mechanisms in Sections 2 and 3.
- Losing GLUT4 only in fat tissue makes mice insulin resistant in **muscle and liver too** → fat tissue health controls whole-body glucose use.

The vicious cycle

- Insulin-resistant fat tissue → more FFA in blood
- More FFA → more fat burning and lipid build-up in muscle
- Lipid build-up → muscle insulin resistance
- Muscle insulin resistance → high blood glucose and insulin
- High insulin → more fat storage and fat cell stress → even more FFA

5. Relevance to insulin resistance and disease

- **Obesity and type 2 diabetes:** fasting FFA levels are high in both.
- **Lipid infusion:** raising FFA in healthy people causes insulin resistance within **3–6 hours**.
- **Lowering FFA:** improves insulin action.
- **Metabolic inflexibility:** insulin-resistant muscle cannot switch from fat to glucose after a meal.
- **Liver:** acetyl-CoA from fat burning activates **pyruvate carboxylase** → more **gluconeogenesis** → the liver makes glucose even when it is not needed → higher blood sugar.
- **Beta cells:** long-term high FFA (**lipotoxicity**) harms insulin-producing beta cells.
- **Athlete's paradox:** endurance athletes have a lot of fat inside their muscles but are very insulin sensitive.
- **Why:** their mitochondria burn fat **completely** and quickly, so harmful DAG and ceramides do not build up.
- **Key point:** the **type and location** of fat molecules matter, not total fat.

6. Clinical and treatment implications

Approach	How it helps
Weight loss and healthy diet	Lowers blood FFA and DAG/ceramide in muscle and liver
Regular exercise	Builds more mitochondria, burns fat completely, moves GLUT4 to the membrane even without insulin (via AMPK)
Thiazolidinediones (pioglitazone)	Activate PPARγ, make fat tissue store fat safely, raise adiponectin, lower FFA
Metformin	Activates AMPK, lowers liver glucose production
Less saturated fat	Less ceramide production and less TLR4 activation

7. Conclusion

High levels of fatty acid oxidation reduce glucose uptake and use through two connected mechanisms. The **classic glucose–fatty acid cycle** explains fuel competition: acetyl-CoA, NADH and citrate from fat burning switch off PDH, PFK-1 and hexokinase. The **lipid-signaling model**, which fits human data better, explains that fat-derived molecules — DAG, ceramides and acyl-CoA — together with mitochondrial stress and inflammation, damage the insulin signal (IRS-1 → PI3K → Akt) so that GLUT4 does not reach the cell surface. Insulin-resistant adipose tissue keeps releasing fatty acids, which keeps the cycle going. Understanding this “fat versus sugar” competition helps explain why obesity leads to insulin resistance and type 2 diabetes, and why lowering fat overload — through exercise, weight loss and some medicines — improves insulin sensitivity.

References

1. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet*. 1963;1(7285):785–789.
2. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. *Am J Physiol Endocrinol Metab*. 2009;297(3):E578–E591.
3. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. *Cell*. 2012;148(5):852–871.